Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-1701 in HER2-expressing urothelial carcinoma
CTR20222018Phase 2Terminated
- Sponsor
- Biocytogen
- Start
- Aug 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BB-1701 in transitional cell carcinoma (TCC), sponsored by Biocytogen. Started Aug 2022; status: terminated.
02
Drugs
BB-1701
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20222018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222018.